Early patency
The global utilisation of streptokinase and tissue plasminogen activator (t-PA) for occluded coronary arteries (GUSTO I) trial' has shown the regimen of accelerated t-PA to be superior to other tested thrombolytic strategies in terms of achieving higher early patency and lower mortality. Perhaps more importantly the study demonstrated that suboptimal reperfusion with compromised flow is little better than an artery that remains occluded. 2 The early (90 minute), complete (TIMI grade 3 flow), and sustained reperfusion of the infarct related artery are the most crucial factors in preventing death and impairment of cardiac function following an acute myocardial infarction. 3 Even with optimal thrombolytic therapy only 54% of the patients eligible for thrombolytic treatment in the GUSTO I trial achieved early high grade patency. In contrast, current primary angioplasty studies show that reperfusion rates are generally greater than 90%, and in some studies as high as 98%. 4 8 3). The ability to discharge patients from hospital secure in the knowledge that a further unheralded event is unlikely is reassuring for both the patient and the physician.
Current status of primary angioplasty
The stimulus for the current interest in primary angioplasty came in 1993 from the landmark publications of the three prospective randomised trials, two from the United States78 and one from the Netherlands.4 More recently, the results of the GUSTO IIb angioplasty substudy have been reported.9 This is by far the largest of the completed trials recruiting 1138 patients from centres around the world representing a variety of experience and varying clinical practice. The study was powered to show a difference in the primary composite end point of death, non-fatal reinfarction, and disabling stroke at 30 days. The results show that this end point was reached in 9-6% of the angioplasty group and 13-7% of the accelerated t-PA group (P = 0 033). Mortality was 5*7% and 7%, respectively (NS). Eighty two per cent of those randomised to angioplasty received this treatment 3-8 hours following the onset of pain and 1-3 hours following randomisation. However, the success rate in terms of TIMI-3 flow was only 73%. This was significantly lower than the 90% plus TIMI-3 flow achieved in other contemporary randomised trials and is highly relevant as mortality in the patients with TIMI-3 flow in the GUSTO IIb study was 1 6%, while those with TIMI-0, 1, and 2 flows had a mortality increase of more than 10-fold to 21%, 14%, and 20%, respectively.9 This is, perhaps, the Angioplasty for the treatment of acute myocardial infarction 
months; a reduction considerably greater than the meta-analysis has determined. 4 The point is further illustrated by analysing the subset of patients with the highest mortality. In the Primary angioplasty in myocardial infarction (PAMI) trial patients older than 70 years with an anterior myocardial infarction and a heart rate faster than 100 beats/min treated with thrombolysis had a mortality of 10-4% compared to 2-0% with angioplasty.
The current meta-analysis shows that although the relative mortality reductions are impressive they translate into only a modest absolute benefit because of low mortalities inherent in preferentially recruiting low risk patients into randomised clinical trials. However, critical analysis of the data available suggests that these relative reductions also apply to high risk patients, where the benefit becomes far more substantial than the figures that are quoted in fig 2. The difficulties of performing randomised trials where interventional procedures are involved have forced trials designs that are impractical and difficult to implement according to protocol and may therefore not answer the relevant questions. In this situation more attention should be paid to the mechanisms of benefit and the surrogates of favourable clinical outcomes, avoiding the often heard cry for additional randomised trials, without full understanding of the limitations of their predecessors.
Practical and cost issues
As the data on the benefit of primary angioplasty has become favourable the arguments opposing the use of the procedure have centred on the costs and the difficulty of providing access for most if not all patients. The two most comprehensive primary angioplasty studies have shown that primary angioplasty is no more expensive than thrombolysis particularly if costs are adjusted for survivors and the expenses are considered over one year.16 17 The higher initial cost of primary angioplasty is offset by the increased costs of re-admissions for recurrent ischaemia in the patients treated with thrombolysis. Further cost savings can be achieved by concentrating expertise so that more patients are admitted to fewer, more experienced units. The recognition that many of the traditional non-invasive tests become redundant following the initial determination of coronary anatomy and LV function will allow further refinement of postmyocardial infarction management with further efficiency and cost savings.
Most of the data on primary angioplasty comes from centres experienced in invasive procedures. Performing primary angioplasty is more demanding than the elective use of the procedure. It should be recognised that experience, expertise, and an adequate throughput of patients are essential components for achieving acceptable standards in primary angioplasty, as is the case for elective angioplasty. A recent registry documenting primary angioplasty in 4625 patients showed that units performing more than 40 angioplasties annually for acute myocardial infarction demonstrated significantly better outcomes,'8 while the GUSTO II trial showed improved results in centres performing more than 625 angioplasty procedures a year.7
Implications for current practice Over the past 20 years angioplasty has developed from a crude technique limited in its application to the most common revascularisation procedure for coronary artery disease. It is broadly most effective at treating acute ischaemia, and the greatest mortality benefit is achieved treating acute myocardial infarction. There can no longer be disagreement that for many high risk patients, primary angioplasty offers a cost effective mortality benefit many times greater than conventional treatment. Even more compelling is the use of the procedure for treating patients in situations where there is no effective alternative-where thrombolysis is contraindicated or where complications develop as a result of failed thrombolysis. Units that are able to offer this treatment will achieve substantially better results than those that are only able to offer treatment with intravenous thrombolysis.
In 1971 the benefits of thrombolysis were demonstrated in a controlled randomised trial'9 and in 1985 an overview established the message beyond doubt.20 Yet it took many more years for the treatment to become established practice for all patients. There is now a need to evaluate a further change in treatment and to establish how this can be made available for those who most stand to benefit. The indicators are that with a willingness to change and an appropriate reallocation of current resources the necessary progress can be made. However, recent multicentre data from the GUSTO IIb trial5 suggest that the overall differences between primary angioplasty and accelerated tissue plasminogen activator (t-PA) are rather small, and point to the need for subgroup analysis. High risk patients, and probably patients with a contraindication to thrombolysis, are emerging as those with the best indications for primary angioplasty. After a rather unequal competition between both strategies during the first 10 years of the reperfusion era, an unpleasant and unjustified feeling of revenge has been perceptible behind several affirmations favouring primary angioplasty. We should stop competing and concentrate on the real issues. These include making primary angioplasty available for the subset of patients most likely to benefit from the procedure, and organising adequate referral networks. It must then be the responsibility of every physician to make the best decision after a thorough (but swift) evaluation of the individual patient's situation. Dr Urban.
